Rx of Neuropathic Pain?

For the answer, click here.

Question 2:

NEXT QUESTION »

For the answer, click here.

Question 3:

NEXT QUESTION »

For the answer, click here.

Question 4:

A 35-year-old man with no significant past medical history presents with worsening right shoulder pain that began 2 weeks ago. He reports recent numbness and tingling in the third, fourth, and fifth finger digits bilaterally. Radiographic images were obtained.

NEXT QUESTION »

For the answer, click here.

Question 5:

ANSWER KEY »

Obstructive Sleep Apnea and Hypertension Update: FDA Clears Phase 2 Trial of Lorundrostat, an Oral Aldosterone Synthase Inhibitor

ANSWER KEY:

Question 1. A

Question 2. A

Question 3. D

Question 4. E

Question 5. B

Related Content

January 17th 2025

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Mineralys Therapeutics also expects topline data from its phase 2 study of lorundrostat for the treatment of uncontrolled hypertension or resistant hypertension when used as an add-on therapy.

August 30th 2023

Vertex on the Verge of Breakthrough for Nonopioid Pain Management as NOPAIN Act Takes Effect

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

Grace Halsey

January 13th 2025

Obesity & Pain Management: A Primary Viewpoints Podcast

Suzetrigine, the investigational selective NaV1.8 pain signal inhibitor, with a PDUFA date of Jan 30, could become a first-in-class nonopioid analgesic.

April 27th 2023

FDA Assigns PDUFA Date for TNX-102 SL, a Nonopioid Analgesic for Fibromyalgia

In our latest episode, an obesity medicine physician explains the importance of a comprehensive plan to manage chronic pain in patients with obesity.

January 2nd 2025

Smartphone App Shows Promise for Managing Hypertension in Observational Study

NX-102 SL is a non-opioid, centrally acting analgesic, granted Fast Track designation by FDA.

December 20th 2024

Obstructive Sleep Apnea and Hypertension Update: FDA Clears Phase 2 Trial of Lorundrostat, an Oral Aldosterone Synthase Inhibitor

People with hypertension who adhered to the mobile app demonstrated well-controlled blood pressure over a 12-week observational period.

Related Content

January 17th 2025

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Mineralys Therapeutics also expects topline data from its phase 2 study of lorundrostat for the treatment of uncontrolled hypertension or resistant hypertension when used as an add-on therapy.

August 30th 2023

Vertex on the Verge of Breakthrough for Nonopioid Pain Management as NOPAIN Act Takes Effect

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

Grace Halsey

January 13th 2025

Obesity & Pain Management: A Primary Viewpoints Podcast

Suzetrigine, the investigational selective NaV1.8 pain signal inhibitor, with a PDUFA date of Jan 30, could become a first-in-class nonopioid analgesic.

April 27th 2023

FDA Assigns PDUFA Date for TNX-102 SL, a Nonopioid Analgesic for Fibromyalgia

In our latest episode, an obesity medicine physician explains the importance of a comprehensive plan to manage chronic pain in patients with obesity.

January 2nd 2025

Smartphone App Shows Promise for Managing Hypertension in Observational Study

NX-102 SL is a non-opioid, centrally acting analgesic, granted Fast Track designation by FDA.